ArticleLiver cancer2018
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).
3 registry-linked trialsAbstract read
In one paragraph
Article in Liver cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 350 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
350citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Lenvatinib as an Adjuvant Therapy in Patients With Hepatocellular Carcinoma Following Radical Resection: A Single-Arm and Open-Label Prospective Study
Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors
The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer
Who cites it
350 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Benefit-Risk Assessment of Chinese Medicine Injections for Primary Liver Cancer Based on Multi-criteria Decision Analysis.Chinese journal of integrative medicine · 2024Pooled it
- Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.World journal of gastroenterology · 2024Pooled it
- Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review.Journal of gastrointestinal cancer · 2024Pooled it
- Trial
- Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study.ImmunoTargets and therapy · 2025Trial
- Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.Signal transduction and targeted therapy · 2024Trial
- Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).Cardiovascular and interventional radiology · 2024Trial
- Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.Signal transduction and targeted therapy · 2023Trial
- Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Trial
- Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.Journal for immunotherapy of cancer · 2022Trial
- Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.Scientific reports · 2026Article
- Emerging role of proteomics in advancing diagnosis, prognosis, and treatment of liver cancer.Liver research (Beijing, China) · 2026Review
- PERSoN4: A multiparametric ultrasound model to improve CEUS LI-RADS for HCC.JHEP reports : innovation in hepatology · 2026Article
- Elevated TMEM45B expression promotes liver cancer progression and is associated with MET signaling activation.Scientific reports · 2026Article
- Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.Genes & genomics · 2026Article
- Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.Liver cancer · 2026Article
- Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).Communications medicine · 2026Article
- Habitat-aware radiomics and adaptive 2.5D deep learning predict treatment response and long-term survival in ESCC patients undergoing neoadjuvant chemoimmunotherapy.European journal of nuclear medicine and molecular imaging · 2026Article
- The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
290 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors.
Jian ZhouDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Hui-Chuan SunDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Zheng WangDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Wen-Ming CongDepartment of Pathology, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jian-Hua WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Meng-Su ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia-Mei YangDepartment of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Ping BieInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Lian-Xin LiuDepartment of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
Tian-Fu WenDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Guo-Hong HanDepartment of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Mao-Qiang WangDepartment of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Rui-Bao LiuDepartment of Interventional Radiology, the Tumor Hospital of Harbin Medical University, Harbin, China.
Li-Gong LuDepartment of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zheng-Gang RenDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Min-Shan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhao-Chong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ping LiangDepartment of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Chang-Hong LiangDepartment of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Min ChenEditorial Department of Chinese Journal of Digestive Surgery, Chongqing, China.
Fu-Hua YanDepartment of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wen-Ping WangDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wen-Wu ChengDepartment of integrated treatment, Tumor Hospital of Fudan University, Shanghai, China.
Chao-Liu DaiDepartment of Hepatobiliary and Spleenary Surgery, the Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Wei-Dong JiaDepartment of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Ya-Ming LiDepartment of Nuclear Medicine, the First Hospital of China Medical University, Shenyang, China.
Ye-Xiong LiDepartment of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Oncology, Peking University International Hospital, Beijing, China.
Tian-Shu LiuDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guo-Yue LvDepartment of General Surgery, the First Hospital of Jilin University, Jilin, China.
Yi-Lei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Wei-Xin RenDepartment of Interventional Radiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Hong-Cheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Wen-Tao WangDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Xiao-Ying WangDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Bao-Cai XingDepartment of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Jian-Ming XuDepartment of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Jian-Yong YangDepartment of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ye-Fa YangDepartment of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Sheng-Long YeDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Zheng-Yu YinDepartment of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China.
Bo-Heng ZhangDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Shui-Jun ZhangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wei-Ping ZhouDepartment of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Ji-Ye ZhuDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
Rong LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ying-Hong ShiDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Yong-Sheng XiaoDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Zhi DaiDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Gao-Jun TengDepartment of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Jian-Qiang CaiDepartment of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wei-Lin WangDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jia-Hong DongDepartment of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Qiang LiDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Feng ShenDepartment of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shu-Kui QinDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Jia FanDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. SUMMARY: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. KEY MESSAGES: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.
Indexed as
CancerCarcinomaChinaDiagnosisLiverTreatment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.